Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Bruce L. Levine(University of Pennsylvania), Marcelo C. Pasquini(Medical College of Wisconsin), John E. Connolly(Parker Institute for Cancer Immunotherapy), David L. Porter(University of Pennsylvania), Michael P. Gustafson(Mayo Clinic Hospital), Jaap Jan Boelens(Memorial Sloan Kettering Cancer Center), Edwin M. Horwitz(Emory University), Stephan A. Grupp(Children's Hospital of Philadelphia), Marcela V. Maus(Harvard University), Frederick L. Locke(Moffitt Cancer Center), Fabio Ciceri(Vita-Salute San Raffaele University), Annalisa Ruggeri(Vita-Salute San Raffaele University), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Helen E. Heslop(Baylor College of Medicine), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Carl H. June(Parker Institute for Cancer Immunotherapy), Anna M. Sureda(Institut d'Investigació Biomédica de Bellvitge), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center)
Nature Medicine
January 9, 2024
Cited by 195Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis